Theo-Dur was not pulled from the market for safety or effectiveness concerns. Its manufacturer, Schering Corporation, voluntarily requested withdrawal of the product in March 2003, and the FDA formally withdrew approval effective June 4, 2004. The FDA investigated and confirmed that the discontinuation was a business decision, not a regulatory action driven by harm to patients.
That said, the story behind Theo-Dur’s disappearance is more nuanced than a simple corporate choice. By the time it left the market, the drug it delivered, theophylline, had already been largely displaced by newer asthma medications that were easier to use, safer, and didn’t require regular blood tests to manage.
What Theo-Dur Was
Theo-Dur was a brand-name extended-release tablet containing theophylline, a medication that relaxes the muscles surrounding the airways in the lungs. It works primarily by blocking an enzyme called phosphodiesterase in airway smooth muscle, which allows the airways to open wider. Theophylline also blocks the effects of adenosine, a natural compound in the body that can trigger airway constriction. For decades, theophylline-based drugs like Theo-Dur were a cornerstone of asthma and chronic obstructive pulmonary disease (COPD) treatment.
The Real Reasons Behind the Discontinuation
The FDA’s official determination is clear: Theo-Dur was “not withdrawn for reasons of safety or effectiveness.” The agency continues to list it in the “Discontinued Drug Product List” section of its Orange Book, a category specifically reserved for products pulled for reasons other than patient harm. The product remains listed there to this day, following a 2022 Federal Register notice that reaffirmed this determination.
While Schering Corporation never published a detailed public explanation, the timing tells the story. By 2003, theophylline had been steadily falling out of favor in clinical practice. Inhaled corticosteroids had become the preferred first-line treatment for persistent asthma, and long-acting bronchodilator inhalers offered airway relief without the complications theophylline carried. Demand for branded theophylline products was declining, and generic versions were already available. Maintaining a brand-name product with shrinking market share simply stopped making financial sense.
Why Theophylline Fell Out of Favor
Theophylline has one of the narrowest therapeutic windows of any commonly prescribed drug. The concentration needed to open airways effectively sits between 10 and 20 micrograms per milliliter of blood. Below 10, the drug doesn’t do much. Above 20, side effects become unacceptably common. Above 35, patients face serious risks including seizures and dangerous heart rhythm problems. That leaves very little room for error.
Even within the therapeutic range, patients frequently experience nausea, vomiting, abdominal cramps, tremors, restlessness, and a rapid heartbeat. These aren’t rare side effects reserved for overdose situations. They’re part of the everyday experience for many people taking the drug, which is one reason clinicians have increasingly targeted an even lower blood level of 5 to 15 micrograms per milliliter.
Constant Monitoring Requirements
Staying in that narrow safe zone required regular blood draws. Patients needed their theophylline levels checked when starting the drug, after every dose change, during any new illness, and whenever symptoms suggested the level might be off. For extended-release formulations like Theo-Dur, blood had to be drawn at a specific time window, 4 to 12 hours after taking the tablet, and only after three days at a steady dose. Missing doses, taking them at irregular intervals, or timing the blood draw wrong could all produce misleading results.
A Long List of Drug Interactions
Theophylline is broken down in the liver by a specific enzyme system called CYP1A2, and an enormous number of common medications and substances interfere with that process. Ciprofloxacin, a widely prescribed antibiotic, causes large increases in theophylline blood levels. Erythromycin, another common antibiotic, slows theophylline clearance. Even cimetidine, an over-the-counter heartburn medication, raises theophylline concentrations.
Interactions ran in the other direction too. Anti-seizure medications like phenytoin speed up theophylline metabolism, potentially making it ineffective. Theophylline can cancel out the effects of sedative medications. It interacts with thyroid hormone replacement, methotrexate, and many others. Even smoking matters: tobacco smoke revs up the liver enzyme that clears theophylline, so smokers need higher doses, and anyone who quits smoking while on theophylline risks a sudden spike in blood levels that could become toxic.
For patients taking multiple medications, which describes most people with chronic lung disease, theophylline became a constant balancing act.
What Replaced Theo-Dur
Current asthma treatment guidelines tell the story of theophylline’s demotion. For mild persistent asthma, low-dose inhaled corticosteroids are the preferred treatment. Theophylline appears only as an alternative option, on equal footing with other second-tier choices. For moderate persistent asthma, the preferred approach combines a low-dose inhaled corticosteroid with a long-acting inhaled bronchodilator. Theophylline again appears only as an alternative if that combination isn’t suitable. Even in severe persistent asthma, theophylline is listed as a backup, not a first choice.
Inhaled corticosteroids offered something theophylline couldn’t: targeted delivery directly to the lungs with minimal effects on the rest of the body. They address the underlying inflammation driving asthma, not just the muscle tightness in the airways. Long-acting inhaled bronchodilators, paired with those corticosteroids, provided the airway-opening effects patients needed without the blood tests, the drug interactions, or the razor-thin margin between a helpful dose and a harmful one.
Theophylline Is Still Available
The Theo-Dur brand is gone, but generic extended-release theophylline tablets remain on the market. Some patients with difficult-to-control asthma or COPD still use theophylline as an add-on therapy when first-line treatments aren’t enough. Its low cost makes it particularly relevant in parts of the world where inhaled corticosteroids are less accessible. More recent research has even suggested that theophylline at lower doses may have anti-inflammatory effects beyond simple bronchodilation, working through a different mechanism that reduces the activity of inflammatory genes in the lungs.
So while the Theo-Dur brand disappeared because the market moved on, the active ingredient hasn’t vanished entirely. It simply shifted from a leading role to a supporting one.